Showing 1 - 20 results of 73 for search 'Massimo Breccia', query time: 0.06s Refine Results
  1. 1
    Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib

    Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib by Massimo Breccia

    Published 2015-10-01
    Get full text
    Article
  2. 2
    Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome

    Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome by Massimo Breccia

    Published 2015-10-01
    Get full text
    Article
  3. 3
    Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached

    Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached by Massimo Breccia

    Published 2020-02-01
    Get full text
    Article
  4. 4
    SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

    SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs by Massimo Breccia, Giuliana Alimena

    Published 2014-01-01
    Get full text
    Article
  5. 5
    Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia

    Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia by matteo molica, elisabetta abruzzese, massimo breccia

    Published 2020-08-01
    Get full text
    Article
  6. 6
    MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY

    MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY by Francesco Lococo, Roberto Latagliata, Massimo Breccia

    Published 2013-06-01
    Get full text
    Article
  7. 7
    Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

    Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia by Matteo Molica, Emilia Scalzulli, Gioia Colafigli, Robin Foà, Massimo Breccia

    Published 2019-02-01
    Get full text
    Article
  8. 8
    Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

    Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia by Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

    Published 2016-02-01
    Get full text
    Article
  9. 9
    MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

    MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine by Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Paola Finsinger, Alessandra Serrao, Giuliana Alimena

    Published 2012-02-01
    Get full text
    Article
  10. 10
    The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)

    The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply) by Giuseppe Visani, Massimo Breccia, Enrico Montefusco, Enrica Morra, Valeria Santini, Alessandro Isidori

    Published 2011-04-01
    Get full text
    Article
  11. 11
    Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

    Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase by Fausto Castagnetti, Fausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia

    Published 2021-03-01
    Get full text
    Article
  12. 12
    Editorial: Risk-stratification in myelodysplastic syndromes

    Editorial: Risk-stratification in myelodysplastic syndromes by Massimo Breccia, Francesca Vinchi, Francesca Vinchi, Massimiliano Bonifacio, Gianni Binotto, Gang Zheng

    Published 2022-12-01
    Get full text
    Article
  13. 13
    Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

    Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia by Massimo Breccia, Elisabetta Abruzzese, Mario Annunziata, Luigia Luciano, Simona Sica, Simona Sica

    Published 2021-03-01
    Get full text
    Article
  14. 14
    A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

    A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase by Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro, Jorge E. Cortes

    Published 2022-07-01
    Get full text
    Article
  15. 15
    Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

    Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes by Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

    Published 2011-10-01
    Get full text
    Article
  16. 16
    The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS

    The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS by Massimo Breccia, Giuseppina Loglisci, Paola Finsinger, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

    Published 2011-12-01
    Get full text
    Article
  17. 17
    Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia

    Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia by Massimo Breccia, Laura Cicconi, Clara Minotti, Roberto Latagliata, Laura Giannì, Francesco Lo-Coco

    Published 2011-09-01
    Get full text
    Article
  18. 18
    Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

    Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia by Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco

    Published 2007-09-01
    Get full text
    Article
  19. 19
    Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation

    Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation by Massimo Breccia, Roberto Latagliata, Laura Cannella, Clara Minotti, Giovanna Meloni, Francesco Lo-Coco

    Published 2010-05-01
    Get full text
    Article
  20. 20
    Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib

    Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib by Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, Maria L. Bisegna, Maurizio Martelli, Massimo Breccia

    Published 2025-01-01
    Get full text
    Article

Search Tools: